Discover
Skyrizi (risankizumab) / AbbVie, Boehringer IngelheimStudy of Subcutaneous Risankizumab Injection to Assess Change in Palmoplantar Pustulosis Area and Severity Index [PPPASI] in Adult Japanese Participants With Palmoplantar Pustulosis (clinicaltrials.gov) - Jun 30, 2020 - P3; N=116; Not yet recruiting; Sponsor: AbbVie
Siliq (brodalumab) / Bausch Health, LEO Pharma, Kyowa Hakko KirinEfficacy and safety of brodalumab in adolescents from 12 to 17 years of age with moderate-to-severe plaque psoriasis (clinicaltrialsregister.eu) - Jun 30, 2020 - P3; N=120; Sponsor: LEO Pharma A/S
Ilumya (tildrakizumab-asmn) / Sun Pharma, AlmirallSun Pharmaceutical Industries receives Japan MHLW approval for Ilumya (Business Standard) - Jun 29, 2020 - "Sun Pharmaceutical Industries announced that one of its wholly-owned subsidiaries has received approval from the Ministry of Health, Labour and Welfare (MHLW), Japan for Ilumya (tildrakizumab) for the treatment of plaque psoriasis in adult patients who have an inadequate response to conventional therapies."
AVT02 (adalimumab biosimilar) / Cipla, AlvotechPharmacokinetic, Efficacy, Safety, and Immunogenicity of AVT02 With Moderate to Severe Chronic Plaque Psoriasis (clinicaltrials.gov) - Jul 1, 2020 - P3; N=448; Not yet recruiting; Sponsor: Alvotech Swiss AG
bimekizumab (UCB4940) / UCB; Humira (adalimumab) / Eisai, AbbVieBE OPTIMAL: A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis (clinicaltrials.gov) - Jul 1, 2020 - P3; N=840; Recruiting; Sponsor: UCB Biopharma SRL; Suspended --> Recruiting
bimekizumab (UCB4940) / UCBBE COMPLETE: A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis (clinicaltrials.gov) - Jul 1, 2020 - P3; N=390; Recruiting; Sponsor: UCB Biopharma S.P.R.L.; Suspended --> Recruiting
